HilleVax’s $200 Million Initial Public Offering

Latham & Watkins represented HilleVax, while Davis Polk advised the joint book-running managers in the IPO. HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and…

This content is for members only.
Login to Read More Join Now
Laura Testa

Author: Laura Testa

This content is for members only.
Login to Read More Join Now